Augmentation of cell therapy efficacy including treatment with alpha 1-3 fucoslytransferase

Abstract

Disclosed are methods, compositions of matter, and kits useful for augmentation of cells through modification of cellular membrane properties following ex vivo treatment.

What is claimed is: 
     
         1 . A method of enhancing homing and engraftment of a T cell population, the method comprising the step of:
 administering a population of modified T cells to a patient in need thereof, the population of cells being modified by contact with an α1,3-fucosyltransferase that modified at least one surface molecule on the T cells to enhance selectin mediated binding thereof.   
     
     
         2 . The method of  claim 1 , wherein the α1,3-fucosyltransferase is selected from a group consisting of α1,3-fucosyltransferase I; α1,3-fucosyltransferase III; α1,3-fucosyltransferase IV; α1,3-fucosyltransferase V; α1,3-fucosyltransferase VI; α1,3-fucosyltransferase VII; α1,3-fucosyltransferase IX; and combinations thereof. 
     
     
         3 . The method of  claim 1 , wherein the T cell population is further defined as a heterogeneous population of T cells. 
     
     
         4 . The method of  claim 1 , wherein the T cell population comprises Regulatory T cells. 
     
     
         5 . The method of  claim 4 , wherein the α1,3-fucosyltransferase comprises α1,3-fucosyltransferase VI. 
     
     
         6 . The method of  claim 1 , wherein the T cell population comprises Cytotoxic T cells. 
     
     
         7 . The method of  claim 6 , wherein the α1,3-fucosyltransferase comprises α1,3-fucosyltransferase VII. 
     
     
         8 . The method of  claim 1 , wherein the patient suffers from at least one condition selected from the group consisting of a myelodysplastic syndrome, a stem cell disorder, a myeloproliferative disorder, a lymphoproliferative disorder, a phagocyte disorder, a histiocytic disorder, a liposomal storage disease, a congenital immune system disorder, an inherited erythrocyte abnormality, an inherited platelet abnormality, a plasma cell disorder, a tumor, an autoimmune disease, and combinations thereof. 
     
     
         9 . The method of  claim 1 , wherein the patient in need of treatment with the modified cell population suffers from at least one condition selected from the group consisting of peripheral arterial diseases, ischemic limb injury, diabetes, heart disease, liver disease, bone disease, muscular dystrophy, Alzheimer's disease, ALS, multiple sclerosis, Parkinson's disease, spinal cord injury, stroke, head trauma, infertility, and combinations thereof. 
     
     
         10 . The method of  claim 1 , wherein the population of modified T cells is administered to a site of injury or proximal thereto. 
     
     
         11 . A method of enhancing homing and engraftment of one or more T cells, the method comprising the step of:
 contacting one or more T cells with an α1,3-fucosyltransferase to modify at least one surface molecule on the T cell(s) to enhance selectin mediated binding thereof.   
     
     
         12 . The method of  claim 10 , wherein the α1,3-fucosyltransferase is selected from a group consisting of α1,3-fucosyltransferase I; α1,3-fucosyltransferase III; α1,3-fucosyltransferase IV; α1,3-fucosyltransferase V; α1,3-fucosyltransferase VI; α1,3-fucosyltransferase VII; α1,3-fucosyltransferase IX; and combinations thereof. 
     
     
         13 . The method of  claim 11 , wherein the T cell population comprises Regulatory T cells. 
     
     
         14 . The method of  claim 13 , wherein the α1,3-fucosyltransferase comprises α1,3-fucosyltransferase VI. 
     
     
         15 . The method of  claim 11 , wherein the T cell population comprises Cytotoxic T cells. 
     
     
         16 . The method of  claim 15 , wherein the α1,3-fucosyltransferase comprises α1,3-fucosyltransferase VII. 
     
     
         17 . A method of enhancing homing and engraftment of one or more Cytotoxic T cells, the method comprising the step of:
 contacting one or more Cytotoxic T cells with α1,3-fucosyltransferase VII to modify at least one surface molecule on the Cytotoxic T cell(s) to enhance selectin-mediated binding thereof.